secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elanco Animal Health Inc (ELAN)
CIK:        0001739104
Form:       8-K
Filed at:   2025-05-07T23:59:59+00:00
Accession:  0001739104-25-000040
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elanco Q1 beats; FY25 revenue raised to $4.51-4.58B; debt paydown accelerated
-----------------------------------------------------------------------------

- Q1 revenue $1,193M (-1% reported, +4% organic CC); adj EPS $0.37 vs $0.34 YoY, above guidance.
- FY25 revenue guidance raised to $4,510-$4,580M on FX tailwind; adj EBITDA guidance unchanged at $830-$870M.
- Accelerating debt paydown: gross debt reduction $450-500M expected; net leverage target improved to 3.9x-4.3x.
- Pet Health revenue $635M (-1%); Credelio Quattro ~10% share; Zenrelia in 11,000 clinics (35% penetration).
- Q2 guidance: revenue $1,175-$1,195M, adj EPS $0.17-$0.21; organic constant currency growth 4-6%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739104/000173910425000040/0001739104-25-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739104/000173910425000040/elan-20250507.htm
  HTML page:      https://secwatch.observer/filing/0001739104-25-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer